1 Analytical validation of HepatoPredict kit to assess hepatocellular carcinoma

2 prognosis prior to a liver transplantation.

3

- 4 Maria Gonçalves-Reis, MSc¹, Daniela Proença, BSc¹, Laura P. Frazão, PhD¹, João L. Neto, PhD¹, Sílvia
- 5 Silva, MD², Hugo Pinto-Marques, MD PhD^{2,3}, José B. Pereira-Leal, PhD¹, Joana Cardoso, PhD^{1*}

6

- 7 1- Ophiomics Precision Medicine, Lisbon, Portugal
- 8 2- Hepato-Biliary-Pancreatic and Transplantation Centre, Curry Cabral Hospital, Centro Hospitalar
- 9 Universitário de Lisboa Central, Lisbon, Portugal;
- 10 3 Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa
- 11 (NMS/UNL), Lisbon, Portugal

12

- 13 * Corresponding author: Joana Cardoso, PhD: jvaz@ophiomics.com; Ophiomics Precision Medicine,
- 14 Pólo Tecnológico de Lisboa, Rua António Champalimaud, Lote 1 (Sala 14); 1600-514 Lisbon, Portugal.

15

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 Abstract

17 <u>Background:</u> The best curative treatment for hepatocellular carcinoma (HCC) is liver transplant (LT), but 18 the limited number of organs available for LT dictates strict eligibility criteria. Despite this patient 19 selection stringency, current criteria often fail in pinpointing patients at risk of HCC relapse and in 20 identifying good prognosis patients that could benefit from a LT. HepatoPredict kit was developed and 21 clinically validated to forecast the benefit of LT in patients diagnosed with HCC. By combining clinical 22 variables and a gene expression signature in an ensemble of machine learning algorithms, 23 HepatoPredict stratifies HCC patients according to their risk of relapse after LT.

Methods: Aiming at the characterization of the analytical performance of HepatoPredict kit in terms of sensitivity, specificity and robustness, several variables were tested which included reproducibility between operators and between RNA extractions and RT-qPCR runs, interference of input RNA levels or varying reagent levels. The described methodologies, included in the HepatoPredict kit, were tested according to analytical validation criteria of multi-target genomic assays described in guidelines such as ISO201395-2019, MIQE, CLSI-MM16, CLSI-MM17, and CLSI-EP17-A. Furthermore, a new retrained version of the HepatoPredict algorithms is also presented and tested.

31 <u>**Results:**</u> The results of the analytical performance demonstrated that the HepatoPredict kit performed 32 within the required levels of robustness (p > 0.05), analytical specificity (inclusivity ≥ 95 %), and 33 sensitivity (LoB, LoD, linear range, and amplification efficiency between 90 - 110 %). The introduced 34 operator, equipment, input RNA and reagents into the assay had no significant impact on HepatoPredict 35 classifier results. As demonstrated in a previous clinical validation, a new retrained version of the 36 HepatoPredict algorithm still outperformed current clinical criteria, in the accurate identification of HCC 37 patients that more likely will benefit from a LT.

38 <u>Conclusions:</u> Despite the variations in the molecular and clinical variables, the prognostic information 39 obtained with HepatoPredict kit and does not change and can accurately identify HCC patients more 40 likely to benefit from a LT. HepatoPredict performance robustness also validates its easy integration 41 into standard diagnostic laboratories.

42

- 43 Keywords: HepatoPredict, Liver cancer, Hepatocellular carcinoma, Liver transplantation, Analytical
- 44 validation, Multi-target genomic assay, Prognostic test.

46 Background:

47 Primary liver cancer is the 6th most diagnosed cancer and the third leading cause of cancer death 48 worldwide [1]. Hepatocellular carcinoma (HCC) comprises 75-85 % of primary liver cancer cases and it 49 is associated with chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), aflatoxin-50 contaminated foods, heavy alcohol intake, excess body weight, type 2 diabetes, and smoking [1]. About 51 30% of HCC cases are considered for treatment with curative intent [2] which involves liver transplantation (LT) or surgical resection [2,3]. In contrast with surgical resection, LT treats the HCC as 52 53 well as the underlying cirrhosis, reducing the patient's risk of death within the first 2 years of 54 diagnosis [3]. However, due to the shortage of liver donors, several different criteria mainly based on 55 tumor burden and protein biomarkers such as alpha-fetoprotein (AFP) and des-y carboxyprothrombin 56 (DCP), have been developed for the identification of HCC patients most likely to benefit from LT [4–13]. 57 Nevertheless, the limitations of these criteria are currently under discussion, mainly because they 58 exclude patients with an underlying good prognosis who can benefit from a LT and include bad 59 prognosis patients that will not benefit from the surgery [14,15].

60

61 The HepatoPredict kit intends to predict which patients diagnosed with HCC have a good prognosis and 62 thus will benefit from a LT. This is achieved by combining three clinical variables (tumor number, size 63 of the largest nodule, and total tumor volume) and a gene expression signature (includes DPT, CLU, 64 CAPNS1, and SPRY2 genes) and a proprietary algorithm. In short, the HepatoPredict kit can extract RNA 65 from formalin-fixed paraffin-embedded (FFPE) HCC samples and to perform gene expression analysis 66 through real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) technology. 67 The RT-qPCR results are then combined with the clinical data using a machine learning algorithm that 68 returns three different values concerning the predictive value (Class I and II) or its absence (Class 0) [16] 69 (Figure 1).

71 In a previous study [16], using a retrospective clinical validation cohort of patients diagnosed with HCC, 72 we have demonstrated that HepatoPredict outperforms the Milan [4], University of California San 73 Francisco (UCSF) [6], Up-to-seven [11], alpha fetoprotein (AFP) [7], Metroticket 2.0 [5], Total Tumour 74 Volume (TTV) [13], and TTV AFP [12] criteria in the selection of patients suitable for LT¹⁶. Apart from 75 its clinical utility, the technical performance of a prognostic test used in the diagnostic setting must also 76 be verified through its capacity to generate specific, sensitive, and robust data under standard 77 laboratory conditions (analytical validation). The aim of this work is to present evidence of the analytical 78 validation of the HepatoPredict kit based on comprehensive technical studies (Figure 1). This validation 79 also included the re-training of the HepatoPredict algorithm using a retrospective cohort of 162 80 patients diagnosed with HCC and submitted to LT.

- 81
- 82



Figure 1 – HepatoPredict kit Analytical Validation. The HepatoPredict kit intends to predict tumor
 recurrence after a liver transplant in patients with HCC. The HepatoPredict kit uses FFPE HCC samples
 from which the RNA is extracted and subsequently used as a template in 1-step RT-qPCR reactions

targeting reference genes (*RPL13A*, *GAPDH*, *TBP*), genes of interest (*DPT*, *CLU*, *CAPNS1*, *SPRY2*) and a genomic DNA control (*Chr3*). Gene expression levels of the genes of interest are normalized to the geometric mean of the reference genes and combined with clinical variables through an algorithm. The analytical validation of the HepatoPredict kit comprised several different assays performed at different steps of the kit: validation of the RNA extraction methodology, analytical specificity, sensitivity, efficiency, and robustness of RT-qPCR reactions and univariate and multivariate analysis of the HepatoPredict algorithm.

93 Methods:

94 Samples: In this study, HCC samples preserved as FFPE tissue were used. FFPE HCC samples were 95 acquired from four different suppliers: Biobank IRBLleida (PT20/00021), integrated in the Spanish 96 National Biobanks Network and Xarxa de Bancs de Tumors de Catalunya (XBTC) sponsored by Pla 97 Director d'Oncología de Catalunya; Biobank ISABIAL, integrated in the Spanish National Biobanks 98 Network and in the Valencian Biobanking Network; and biorepositories from Amsbio (US) and Biotech 99 (US). All samples were processed following standard operating procedures with the appropriate 100 approval of the Ethical and Scientific Committees. Moreover, clinical samples from a retrospective 101 clinical study approved by the ethics authorities and taking place in the Curry Cabral Hospital (Lisbon, 102 Portugal), were also used. All HCC FFPE samples were acquired either sectioned with 3-5 µm thickness 103 or as paraffin blocks that were then cut in 3-5 μ m thick slices using a microtome (Leica SM2010R Sliding 104 Microtome, Leica Biosystems) and mounted on a glass slide.

105

106 Histopathologic analysis: Prior to RNA extraction, HCC FFPE samples were analyzed by a certified 107 pathologist using an hematoxylin and eosin (H&E) stained tumor section. FFPE HCC slides (3 μ m thick) 108 were first deparaffinized and stained using Harris Hematoxylin solution (#3801561E, Leica Biosystems, 109 Richmond, USA. The slide was then counterstained with Eosin Y solution (#2801601, Leica Biosystems, 110 Richmond, USA). Finally, slides were dehydrated in increasing alcohol concentrations, cleared in xylene 111 (#28973, VWR, Alfragide, Portugal), and mounted using a xylene-based mounting medium (#107961, 112 Merck, Darmstadt, Germany). After H&E staining, slides were observed under an optical upright 113 microscope (Panther L, #1100104600142, Motic[®]).

114

115 <u>RNA extraction:</u> For RNA extraction, an HCC area mimicking a needle biopsy was delimited in two 116 sequential 5 μm slides. Samples were initially deparaffinized and the RNA was extracted using the 117 RNeasy FFPE Kit (#73504, Qiagen, Hilden, Germany), according to the manufacturer's instructions with 118 two exceptions: proteinase K cell lysis and final elution volume.

1	1	9
		/

- 120 DNA extraction: DNA was extracted from HCC FFPE samples using the QIAamp DNA FFPE Tissue Kit
- 121 (#56404, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions.

122

123 <u>RNA extraction method validation:</u> For the validation of the RNA extraction method, 87 FFPE HCC 124 samples (from the four different suppliers) were used. Each sample was tested in duplicate and by two 125 different operators. Moreover, mirror sections of each sample were used to reduce the variability 126 between operators. Immediately after extraction, RNA was stored at -20 °C until further usage or used 127 straight away in RT-qPCR reactions (conditions described below) targeting *RPL13A* (reference gene) and 128 *Chr3* (genomic DNA control) to analyze the integrity [17] and the purity of the RNA samples, 129 respectively.

130

<u>RT-qPCR reactions:</u> 1-step RT-qPCR reactions were performed as previously described [16]. The
 QuantStudio Design & Analysis Software v1.5.1 software was used for data acquisition and analysis. For
 gene expression normalization, the geometric mean of the cycle threshold (Cq) of the reference genes
 (*RPL13A, GAPDH,* and *TBP*) was subtracted from the Cq values of the genes of interest (*DPT, CLU, CAPNS1,* and *SPRY2*).

136

137 Primer Specificity: RT-qPCR products were sequenced via Sanger sequencing outsourced to Eurofins 138 (https://eurofinsgenomics.eu/en/custom-dna-sequencing/gatc-services/supremerun-tube/). In total, 139 16 different solutions (forward and reverse for 8 targets) were sent to Eurofins. Regarding RT-qPCR 140 products, a 2-step RT-qPCR reaction was performed using the SuperScript™ VILO™ cDNA Synthesis Kit 141 (#11754050, Thermo Fisher Scientific, Bleiswijk, Netherlands) to synthetize cDNA and the InvitrogenTM 142 Platinum[™] SuperFi[™] PCR Master Mix with the SuperFi[™] GC Enhancer (#12358010, Thermo Fisher 143 Scientific, Bleiswijk, Netherlands) in qPCR. An RNA pool (composed of 8 different FFPE HCC samples) 144 was used as template. The size of each RT-qPCR product was assessed by electrophoresis in a 4 %

agarose gel (#G401004, Thermo Fisher Scientific, Bleiswijk, Netherlands), using a DNA ladder
(#10488096, Thermo Fisher Scientific, Vilnius, Lithuania) and nuclease-free water (#129114, Qiagen,
Hilden, Germany) as a negative control in an electrophoresis system (#G8300, Thermo Fisher Scientific,
Vilnius, Lithuania).

149

<u>RT-qPCR inclusivity</u>: Different FFPE HCC samples were used as templates in RT-qPCR reactions targeting
 all the genes included in HepatoPredict kit. Each RT-qPCR reaction was performed in duplicate and by
 two different operators. For each sample, each operator used the same batch of extracted RNA or DNA.
 Both nucleic acid extraction and RT-qPCR reactions were performed as described above.

154

155 Limit of Detection (LoD) determination: For LoD determination, a pool composed of 8 FFPE HCC samples 156 was used. The samples composing the pool reflected high and low expression levels of each target and 157 were associated with a bad prognosis (recurrence, n = 4) and a good prognosis (no recurrence, n = 4). 158 Both pools, of DNA and RNA, were created using the same samples. DNA pool was directly used for 159 serial dilutions (at least 11 per target) and the RNA pool was diluted 1:4 to create the starting sample 160 for the serial dilutions. In total, 21 replicates were done for each dilution (triplicates in each of the 7 161 RT-qPCR reactions), per lot number of reagents, on three different days (2-3 RT-qPCR reactions per 162 day). For each target, all reactions were performed by the same operator with the same equipment. 163 RT-qPCR reactions using reagents from different lots were analyzed separately. Data was analyzed in 164 accordance with the Probit model, which implied the creation of a regression representing the 165 probability vs \log_2 dilution for each target assuring at least 3 dilutions with hit rates within 0.10 - 0.90 166 and at least one exceeding 0.95. Moreover, to minimize the influence of the model limit ranges of 167 probability, dilutions with a 100 % fail or success rate were included in each analysis. LoDs were 168 independently calculated for each lot and the maximum LoD (concentration) was taken as the reported 169 value for the measurement procedure. To determine the Cq value associated with the LoD, a linear 170 regression was applied between the Cq values and the log_2 (dilution factor). All the log_2 (dilution factor) 171 until the one immediately after the LoD were considered. The values outside the confidence interval 172 (CI) at 99 % were considered outliers and were removed. Linear, quadratic, and cubic polynomial 173 functions were fitted to the Cq values using log₂ dilution values. If none of the non-linear coefficients 174 was different from zero, the target was considered linear (*GAPDH*, *TBP* and *Chr3*). Otherwise, the 175 absolute difference between the model that best fits the data (smallest mean squared error) and the 176 linear model was calculated. When the difference was less than 1 Cq value, the target was considered 177 linear (*RPL13A*, *DPT*, *CAPNS1*, *CLU* and *SPRY2*).

178

179 Linearity: The linear range of each target included in the HepatoPredict kit was determined for RT-qPCR 180 reactions using FFPE HCC samples (previously used for LoD determination) and reference materials 181 (#636690, Takara, Saint Germain en Laye, France) to cover a broad range of nucleic acids 182 concentrations in linearity determination. For that, seven serial dilutions of reference RNA were used 183 with 3 replicates per dilution and at least eleven dilutions of nucleic acids pools, obtained from HCC 184 FFPE samples, were used with 7 replicates per dilution. Finally, the Cq values and the dilution factors 185 were plotted in a base 2 logarithmic graph and R² (> 0.90) was calculated for all targets.

186

187Amplification efficiency: The reaction efficiency was calculated for each target included in the188HepatoPredict kit. It was determined from the slope of the log-linear portion of each target curve:189amplification efficiency = $(2^{-1/slope} - 1) \times 100$.

190

191Robustness of RT-qPCR reactions: Plackett and Burman tables [18] were used to design the robustness192assay: alterations in the concentrations (\pm 30 %) of the master mix (#A15300, Thermo Fisher Scientific,193Bleiswijk, Germany), primers and probes were implemented as well as different final reaction volumes194(\pm 5 %) and annealing temperatures (\pm 1 °C), as demonstrated in Table 1. Two independent assays per195each target were performed using the same sample pool (see LoD) in triplicate and all reactions were196performed using sample concentration near the LoD (RNA pool serial dilution 2⁻² and DNA pool without

197 further dilutions). Three standard conditions were incorporated in the assay for data analysis: standard
198 (STD) (no changes), STD1 (-1 °C annealing temperature), and STD2 (+1 °C annealing temperature).
199

200 Determination of Cq values below LoD and within the linear range for each target: Serial dilutions of 201 the reference RNA (#636690, Takara, Saint Germain en Laye, France) were used as templates for RT-202 qPCR reactions targeting all genes included in the HepatoPredict kit. The Cq values above the LoD and 203 outside the linear range for each target were identified and the maximum acceptable Cq value for each 204 target was determined.

205

206 Precision studies: The conditions under which repeated measurements were made determine the type 207 of precision being analyzed - reproducibility (daily, lot-to-lot, operator, and inter-assay) and 208 repeatability. For the daily reproducibility, for the same sample, assays were performed by the same 209 operator, using the same sample and kit's lot on 4 different days. Regarding lot-to-lot reproducibility, 210 the same sample was analyzed by the same operator using kits from three different lots. Finally, 211 operator reproducibility was studied by using the same sample with HepatoPredict kits from the same 212 lot but performed by three different operators. For each condition, two HepatoPredict kits were used 213 (two independent assays). Repeatability was measured considering the triplicates of each 214 HepatoPredict kit run. In total, 3 different HCC FFPE samples were studied, thus, 48 HepatoPredict kits 215 were used (16 kits/sample). To further assess inter-assay reproducibility, 15 additional samples were tested in duplicate by different operators, using different lots of the HepatoPredict kit, and on different 216 217 days (total n = 18).

220 Table 1 – Design of the robustness assay for the HepatoPredict kit.

Eastar	Conditions										
Factor	STD	STD1	STD2	1	2	3	4	5	6	7	8
PCR Equipment	А	А	А	А	А	А	А	А	А	А	А
[Master Mix]	NC	NC	NC	+ 30 %	+ 30 %	- 30 %	- 30 %	+ 30 %	+ 30 %	- 30 %	- 30 %
[Primers]	NC	NC	NC	NC	- 30 %	NC	+ 30 %	NC	- 30 %	NC	+ 30 %
[Probe]	NC	NC	NC	NC	- 30 %	+ 30 %	NC	- 30 %	NC	NC	+ 30 %
Final Reaction Volume	NC	NC	NC	- 5 %	- 5 %	+5%	+5%	+5%	+5%	- 5 %	- 5 %
Annealing Temperature	NC	- 1 °C	+1°C	+1°C	- 1 °C	+1°C	-1°C	-1°C	+1°C	-1°C	+ 1 °C

STD – standard. NC – no changes regarding the standard protocol.

222 HepatoPredict algorithm training: A dataset with 162 patients diagnosed with HCC and submitted to 223 liver transplant was used (**Supplementary File 1**). Concerning the dataset, different models were tested, 224 such as Naive Bayes, support-vector machine (SVM) with different kernel functions, and Extreme 225 Gradient Booster (XGBoost). Moreover, synthetic minority oversampling technique (SMOTE) was also 226 used for data imbalances. Python 3.8 was used with scikit-learn 1.0.2 (1https://scikit-learn.org/stable/), 227 XGBoost 1.6.1 (https://xgboost.readthedocs.io/en/stable), imbalance-learn (https://imbalanced-228 learn.org/stable/), and Optuna 2.10.0 (https://optuna.org/). Each model was fed with 4 molecular (DPT, 229 CLU, CAPNS1, and SPRY2 gene expression) and 3 clinical variables (tumor number, largest tumor size 230 and total tumor volume). As previously described [16], the algorithm was developed as a two-level 231 predictor.

232 HepatoPredict algorithm univariate analysis: The univariate analysis of the HepatoPredict algorithm 233 consisted in calculating the error (i.e., counting each time the algorithm would fail the correct prognosis 234 classification) when altering the Cq mean values of each gene (prior normalization) and varying the 235 normalized Cq values of DPT, CLU, SPRY2 and CAPNS1 and the clinical variables (tumor number, 236 diameter of the largest tumor, and total tumor volume). Thus, Cq mean values of the genes of interest 237 (DPT, CLU, SPRY2 and CAPNS1) were replaced by 40 Cq (the maximum number of cycles allowed) and 238 their respective LoD and the Cq means of the reference genes (RPL13A, GAPDH, and TBP) were 239 removed and replaced by their respective LoD. Regarding the variations of the normalized Cq values 240 (for DPT, CLU, SPRY2 and CAPNS1 genes), variations of 0.1 Cq were performed. Alterations in clinical 241 variables included the variations in the tumor number (1-2 units), and in the diameter of the largest 242 tumor (cm) and the total tumor volume (cm³) by 2 %.

HepatoPredict algorithm multivariate analysis: The multivariate analysis of the HepatoPredict algorithm consisted in calculating the error associated with the alteration of more than one variable at a time. Thus, a range for each variable variation was defined (based on algorithm univariate analysis) and random combinations of 2, 3, 4, 5, 6 and 7 altered variables were tested. All possible combinations of variables were performed and for each combination the assay was repeated 10,000 times with random

- variable alterations within the defined range. Finally, two types of errors were calculated: error type A
- 249 (between Class I and Class II) and error type B (between Class I or II and Class 0).
- 250 <u>Statistical analysis:</u> Statistical analysis was performed using the R language for Statistical Computing (v
- 4.1.1) and GraphPad Prism 7 (GraphPad Software, Inc. 2016). For RNA extraction validation, as the data
- followed a normal distribution, the Paired Student t-test was applied. For robustness assay, Dunn's
- 253 multiple comparisons test was applied. Regarding precision, due to data size, a non-parametric test
- 254 (Friedman test) was used. A *p* < 0.05 was considered statistically significant.

256 Results:

257 Validation of RNA extraction method:

258 For the RNA extraction from HCC FFPE tissues, the RNeasy FFPE kit was used. This RNA extracted 259 method was validated by using 87 HCC FFPE samples handled by two different operators. After 260 extraction, RNA was used as a template in RT-qPCR reactions targeting the RPL13A gene and a DNA-261 specific target (*Chr3*), assuring both the integrity and the purity of the extracted RNA. Each sample was 262 analyzed in duplicate by each operator. Regarding RPL13A expression, no significant differences were 263 observed between operators for each sample (p = 0.27, Figure 2A) and the mean standard deviation 264 (SD) between samples tested by the two operators was 0.47 Cq (Figure 2D). Moreover, no statistically 265 significant differences were observed between each operator's duplicates (p = 0.99 for operator 1 and 266 p = 0.13 for operator 2, Figure 2B and 2C respectively). The mean SD between duplicates of each sample 267 for operator 1 was 0.12 Cq while it was 0.18 Cq for operator 2 (Figure 2D). Regarding Chr3, residual 268 genomic DNA (gDNA) contamination (Cq mean > 34) was identified in 8 samples (9.19 %) handled by 269 operator 2 and in one sample (1.15%) handled by operator 1 (data not shown).

- 270
- 271





- 276 represented (D). For each violin plot (A, B, and C), dots represent Cq mean values (A) and Cq values (B
- and **C)** of *RPL13A* gene. Dashed lines represent the correspondence of samples between groups.
- 278
- 279

280 <u>Analytical specificity – Primer specificity and RT-qPCR inclusivity:</u>

281 To demonstrate primers' uniqueness for each target, primers and RT-qPCR products were sequenced 282 and the specificity of each primer pair was confirmed by aligning the Sanger sequencing 283 electropherograms from each primer with the respective PCR amplicon, as suggested by ISO 284 20395:2019 and MIQE guidelines [19,20]. Before sequencing, the amplicon size was verified by 285 electrophoresis in an agarose gel (Figure 3A, RPL13A depicted as an example). For the RPL13A gene, 286 the electrophoresis band corresponded to 75 bp (Figure 3A), in accordance with the expected amplicon 287 size [16]. All the amplified amplicons (for the remaining HepatoPredict targets) corresponded to the 288 expected size [16] and no extra bands of unspecific PCR products were observed (data not shown) 289 confirming the specificity of the primer pairs for the desired target. The sequences of all primers and 290 probes were successfully aligned for all targets included in the HepatoPredict (data not shown) in the 291 DNA sequence displayed in the Sanger electropherogram of the respective PCR amplicon (Figure 3B-D, 292 example for RPL13A). Due to the very small size of the amplicons (between 71 and 108 bp [16]) and to 293 limit the baseline noise always present at the beginning and end of Sanger electropherograms, the 294 Sanger sequencing was performed for both forward and reverse strands (Figure 3C and 3D, 295 respectively). This allowed for the successful sequencing of forward and reverse primers and respective 296 probe positions in all HepatoPredict amplicons.

297

The inclusivity of the RT-qPCR reactions included in the HepatoPredict kit was demonstrated as described in CLSI-MM17 guideline [21]. An inclusivity of 100 % was demonstrated for all targets, except for *DPT* which had an inclusivity of 95 % (*Supplementary File 2*).

301

302



303 Figure 3 – Primer Specificity (for RPL13A as an illustrative example). After a RT-qPCR reaction targeting 304 the *RPL13A* gene, the size of the amplicon was assessed by electrophoresis in an agarose gel (~75 bp), 305 using a DNA ladder and a negative control (nuclease-free water) (A). ENSEMBL canonical transcript 306 sequence (ENST00000391857.9, RefSeq NM 012423), represented from 5' to 3' (B). Alignment of the 307 RPL13A forward (RPL13A F) and reverse (RPL13A R) primers and probe (RPL13A FAM) with the Sanger 308 sequencing electropherogram results for the *RPL13A* amplicon in forward (5' to 3') (C) and reverse (3' 309 to 5') (D) directions. The presented image is cropped. The full size original image can be found in 310 Supplementary File 3.

311

312 Limit of Detection (LoD), Limit of Blank (LoB), Linearity and Efficiency:

For LoD, LoB, linearity and efficiency determination of each RT-qPCR reaction included in HepatoPredict kit, an RNA pool of FFPE HCC samples was used in accordance with MM16-A guideline [22]. The LoD, for each of the 8 targets included in the HepatoPredict kit, was determined based on ISO 20395:2019, CLSI-MM17, MIQE, and CLSI-EP17-A guidelines [19–21,23]. The Probit model was used, and **Figure 4** exemplifies the application of the model to the *RPL13A* target. The Probit model was applied to two different data sets obtained using different reagent lots (**Figure 4A and 4B**). The LoD was defined as the lowest concentration of target that could be detected in ≥ 95 % of the samples, as represented in Figure 4A and 4B. To determine the Cq value corresponding to the LoD, a linear regression was performed (Figure 4C). For all targets, Pearson's correlation coefficient (R²) was higher than 0.90 (data not shown), except for *Chr3* (R² = 0.73, data not shown). The highest LoD (nucleic acid concentration) between lots was taken as the reported value for the measurement. The LoD of the 7 RNA targets included in the HepatoPredict kit ranged from 34.75 Cq to 36.89 Cq (Table 2). Regarding *Chr3* the LoD was defined at 33.95 Cq (Table 2).

326

To apply the Probit model, it is necessary to assume that all blank or negative samples are reported as negative. These assumptions are true for the HepatoPredict kit, in fact, if a valid Cq value was obtained (< 40 cycles) for just one of the replicates of the NTC (no template control) the entire assay was considered invalid. Thus, the LoB was assumed to be zero, i.e., Cq results for the NTC samples, for all valid RT-qPCR reactions, did not cross the threshold within the 40 cycles and were considered "undetermined" (> 40 Cq).

333

The linear range of each target was also determined in accordance with ISO 20395:2019 [19] with $R^2 = 0.99$ for *RPL13A*, *GAPDH*, *DPT*, and *CAPNS1*, $R^2 = 0.98$ for *TBP* and *CLU*, $R^2 = 0.97$ for *SPRY2* and $R^2 = 0.93$ for *Chr3*. All targets were linear at least within 24.63 and 35.11 Cq (**Table 2**). Moreover, the amplification efficiencies, determined in accordance with ISO 20395:2019 and MIQE guidelines [19,20], ranged from 91.02 to 110.26 Cq for all targets (**Table 2**).

339

Considering that the HepatoPredict kit analyzes 7 different genes and a DNA-specific target, it is
important to assure that all targets can be detected within their linear range and below their LoDs. As
represented in Table 3, the maximum RNA input to assure an ideal performance of the HepatoPredict
kit is 0.031 ng/μL, corresponding to Cq values of 28.26 for *RPL13A*, 28.34 for *GAPDH*, 33.95 for *TBP*,
34.44 for *DPT*, 29.42 for *CLU*, 31.61 for *CAPNS1*, and 33.96 for *SPRY2*.



Log₂(dilution factor)

347 Figure 4 – Estimation of the Limit of Detection (LoD) in Cq values (for *RPL13A* as an illustrative example).

348 The Probit approach was used to determine the LoD of *RPL13A* gene for two different lots of reagents.

349 The LoD was defined as the concentration (\log_2 dilution) at a probability of 95 %. The grey areas

represent the confidence interval at 99 % (A and B). The linear dynamic range was also estimated and

the Cq value associated with the LoD was determined (C). For the example of the *RPL13A* gene, the

highest LoD was obtained with Lot 1 and the correspondent Cq value was 35.75.

353

355

354 Table 2 - LoB, LoD, linear range and PCR efficiency of the 8 targets included in HepatoPredict kit.

Target	LoB	LoD	Linear Ran	Efficiency		
	Cq value	Cq value	Cq value	R^2	%	
RPL13A	> 40	35.75	17.63 – 36.30	0.99	91.02	
GAPDH	> 40	36.32	18.02 - 38.70	0.99	104.76	
TBP	> 40	34.75	24.63 - 39.62	0.98	110.01	

DPT	> 40	35.11	24.41 - 37.68	0.99	102.97
CLU	>40	35.35	19.07 – 39.44	0.98	110.26
CAPNS1	>40	36.89	21.22 - 38.44	0.99	101.79
SPRY2	>40	34.93	23.27 – 38.02	0.97	97.70
Chr3	> 40	33.95	23.90 - 35.11	0.93	91.02

A = 0											
358	Reference			Targets (Cq mean)							
359	RNA (ng/μL)	RPL13A	GAPDH	ТВР	DPT	CLU	CAPNS1	SPRY2			
360	8	20,19	20.40	25.67	25.95	21.38	23.43	25.15			
362	4	21.14	21.20	26.50	20.04	22.44		26.20			
363	4	21.14	21.30	20.59	20.94	22.44	24.45	20.30			
364	2	22.28	22.37	27.66	27.85	23.42	25.46	27.31			
365	1	23.33	23.27	28.82	28.89	24.44	26.45	28.26			
366											
367	0,5	24.06	24.28	29.76	30.02	25.40	27.68	29.26			
368 369	0.25	25.09	25.33	30.67	31.12	26.58	28.70	30.50			
370	0.125	26.12	26.43	31.93	32.04	27.40	29.46	31.34			
371	0.062	27.00	27.47		22.47	20.00					
372	0.063	27.06	27.47	32.76	32.47	28.60	30.75	32.58			
373	0.031	28.26	28.34	33.95	34.44	29.42	31.61	33.96			
374	0.010	20.12	20.20	25.47	25.64		22.96	24.22			
375	0.016	29.12	29.38	35.47	35.04	30.53	32.86	34.33			
376	0.008	30.31	30.34	35.31	36.68	31.79	33.89	37.39			
3/1	0.004	31.20	31.54	36.40	N/A	32.67	35.02	36.80			
370	0.000										
380	0.002	32.36	32.41	N/A	38.06	33.68	37.12	N/A			
381	0.00100	33.22	33.33	37.71	N/A	34.57	37.10	38.47			
382	0.00050	34.41	34.18	N/A	N/A	35.20	38.19	N/A			
383	0.00004		26.21	NI / A	27.10	27.45	20.17	N1/A			
384	0.00024	35.65	36.31	N/A	37.19	37.15	39.17	N/A			
385	0.00012	36.85	37.37	N/A	N/A	N/A	38.75	N/A			

357 Table 3 – Acceptable maximum Cq values for each HepatoPredict kit's target to be detected below their LoD and within the linear range.

7 Cq mean values represented in bold are above the LoD of each target. Between double lines are represented the acceptable maximum Cq values for all targets assuring that all of them are

detected below their LoD and within their linear range: [RNA] = 0.031 ng/µL. N/A – not applicable, Cq > 40.

389 <u>Robustness of RT-qPCR reactions:</u>

390 To study the robustness of the RT-gPCR reactions included in the HepatoPredict kit, alterations in the 391 concentrations and volumes of RT-qPCR reagents were performed as suggested in ISO 20395:2019 [19] 392 and represented in **Table 1**. The Cq mean values of two independent assays obtained for each target 393 under each condition are represented in Figure 5A-C. Conditions with the same annealing temperature 394 were compared with the respective standard condition – conditions 2, 4, 5, and 7 were compared with 395 STD1 (Figure 5B), while conditions 1, 3, 6, and 8 were compared with STD2 (Figure 5C) – and no 396 statistically significant differences were observed (p > 0.05). Furthermore, all conditions (from 1 to 8) 397 were compared with the STD condition representing no changes regarding the initial protocol (Figure 398 **5A**) and no statistically significant differences were observed (p > 0.05).

- 399
- 400



Figure 5 – Robustness of the RT-qPCR reactions included in the HepatoPredict kit. Representation of Cq mean values for each condition (Table 1) of each target included in the HepatoPredict kit. The original condition (STD) (A) was compared with all other conditions (1 to 8) and no statistically significant differences were observed (Dunn's multiple comparisons test). Moreover, conditions with the same annealing temperature were compared with the respective STD condition: (B) STD1 was compared with condition 2, 4, 5 and 7 while (C) STD2 was compared with conditions 1, 3, 6, and 8. No statistically significant differences were observed (Dunn's multiple comparisons test).

409 <u>Precision of the HepatoPredict kit:</u>

410 The precision of the HepatoPredict kit was determined as described in ISO 20395:2019, MIQE, and CLSI-411 MM17 guidelines [19–21]. Precision data was transduced numerically using imprecision values such as 412 standard deviation (SD) and respective confidence interval (CI) at 95 % (Table 4). The HepatoPredict kit 413 reproducibility was verified by normalizing the gene expression level of the genes of interest (DPT, CLU, 414 CAPNS2, and SPRY2) to the geometric mean of the reference genes (RPL13A, GAPDH, and TBP) (Table 415 4), as described for the standard use of the kit. In general, the SD for daily, lot-to-lot, and operator 416 reproducibility were higher for the DPT gene (0.38 – 1.36) when compared with the other genes of 417 interest included in the HepatoPredict kit (0.03 - 0.44). The same was verified for the inter-assay 418 reproducibility (SD calculated between all the independent assays for the same sample) and total SD 419 (square root of the daily, lot-to-lot, and operator variances) (Table 4). Furthermore, while all targets of 420 sample A were associated with higher SD in lot-to-lot reproducibility, sample C presented higher SD 421 values in daily reproducibility. Nevertheless, none of these were observed in sample B, suggesting that 422 the observed variability between independent assays is not dependent on a single factor. In fact, when 423 all varying factors were considered (inter-assay reproducibility and total SD), SD values were similar 424 between both samples. Additionally, inter-assay reproducibility was also determined for 18 different 425 HCC FFPE samples (calculation of the mean SD and respective confidence interval), corroborating the 426 previous results (Table 4). The repeatability was verified for each target included in the HepatoPredict 427 kit – reference genes (Supplementary File 4) and genes of interest (Table 4) – and similar SD were 428 obtained for all targets ranging from 0.05 to 0.14 Cq.

429 Table 4 – Reproducibility of the HepatoPredict kit.

430

Sample	Target	Repeatability	Daily Reproducibility		Lot-to-Lot Reproducibility		Operator Reproducibility		Inter-Assay Reproducibility		Total SD
		(mean SD)	SD	95 % CI	SD	95 % CI	SD	95 % CI	SD	95 % CI	
	DPT	0.07	0.52	0.10-0.93	1.05	0.21 - 1.89	0.81	0.16 - 1.46	0.77	0.55 – 0.99	1.42
Samala A	CLU	0.07	0.11	0.02 - 0.19	0.29	0.06 - 0.53	0.04	0.01 - 0.07	0.28	0.20 - 0.35	0.31
Sample A	CAPNS1	0.07	0.24	0.05 - 0.43	0.35	0.07 – 0.64	0.17	0.04 - 0.37	0.26	0.19 - 0.34	0.46
	SPRY2	0.13	0.08	0.02 - 0.14	0.08	0.02 - 0.14	0.11	0.02 - 0.19	0.18	0.13 - 0.23	0.16
	DPT	0.12	0.38	0.08 - 0.68	0.58	0.12 - 1.05	0.58	0.12 - 1.04	0.81	0.58 - 1.04	0.90
Comple D	CLU	0.08	0.34	0.07 – 0.60	0.30	0.06 - 0.53	0.19	0.04 - 0.35	0.25	0.18 - 0.32	0.49
затріе в	CAPNS1	0.11	0.08	0.02 - 0.14	0.04	0.01-0.07	0.15	0.03 – 0.26	0.13	0.09-0.16	0.17
	SPRY2	0.08	0.03	0.01-0.06	0.12	0.02-0.21	0.29	0.06 - 0.52	0.23	0.17 – 0.30	0.32
	DPT	0.05	1.36	0.27 – 2.45	0.41	0.08 - 0.74	0.84	0.17 – 1.51	0.99	0.71 - 1.26	1.65
Samala C	CLU	0.14	0.31	0.06 - 0.55	0.27	0.05 - 0.48	0.05	0.01-0.09	0.36	0.26-0.47	0.41
Sample C	CAPNS1	0.09	0.10	0.02 - 0.17	0.04	0.01-0.07	0.02	0.00 - 0.03	0.12	0.09 - 0.15	0.11
	SPRY2	0.08	0.44	0.09 - 0.79	0.16	0.03 - 0.28	0.38	0.08 - 0.69	0.47	0.34 - 0.60	0.60
	DPT								0.69	0.53 - 0.84	
All samples	CLU			N/A N/A		N/A			0.26	0.20-0.31	
(n=18)	CAPNS1	N/A						N/A		0.18-0.29	N/A
	SPRY2							0.20	0.16 - 0.25		

431

SD, standard deviation; CI, confidence interval; N/A, not applied.

432 <u>Univariate and multivariate analysis of the new version of the HepatoPredict algorithm:</u>

The HepatoPredict algorithm (V2.0) is a two-level predictor, but the first level (Class I), presents the highest precision and uses the XGboost model (instead of SVM in V1.0) increasing the positive predictive value (PPV) to 96.43 %. The second level (Class II) is a linear SVM model. The variables' weights within each model are represented in *Supplementary File 5*, with *DPT* and *CLU* gene expression levels and total tumor volume being the most important variables of the HepatoPredict algorithm. Furthermore, the new HepatoPredict algorithm was also compared with other clinical criteria for the identification of HCC patients suitable for liver transplantation (*Supplementary File 6*).

440

441 The analytical validation of the new HepatoPredict algorithm consisted in calculating the error (i.e., how 442 many times the correct classification is missed) associated with the alteration of one (univariate) or 443 more (multivariate) variables. Figure 6A represents the error associated with the alteration of the Cq 444 mean values before normalization. The errors were all superior to 10 % demonstrating that to maintain 445 a good HepatoPredict performance, no reference gene can be removed from the assay and the Cq 446 means of the genes cannot be replaced by 40 Cq or its respective LoD. Moreover, the variations allowed 447 for each variable, assuring a maximum error of 5 % (or a maximum variation of 2 Cq or 50 % from the 448 initial value), are represented in Figure 6B-D. In general, it was verified that the DPT normalized gene 449 expression level and the total tumor volume (in cm³) were the variables that least allowed for 450 alterations (for an error = 5 %, variation of \pm 0.4 Cq and \pm 12 %, respectively). On the other hand, CLU 451 normalized gene expression level and the tumor size (the diameter of the largest tumor in cm) were 452 the variables that tolerated greater variations (\pm 3 Cq and \pm 50 % respectively, while maintaining an 453 error < 5 %) (Figure 6C-D). For these variables, the error at 5 % was not used as a threshold for the 454 multivariable analysis, but instead an acceptable absolute variation value was used (± 2 Cq for CLU expression level and \pm 50 % for tumor size). Furthermore, while maintaining an error < 5 %, the tumor 455 456 number was possible to vary in 2 units (Figure 6B) and the normalized gene expression levels of CAPNS1 457 and *SPRY2* varied \pm 1.7 Cq and \pm 1.5 Cq, respectively (**Figure 6D**).

459	The HepatoPredict algorithm multivariate analysis was based on the results presented in Figure 6B-D
460	and demonstrated that the error increases with the number of varying variables (Figure 6E). Moreover,
461	two types of errors were analyzed concerning the final HepatoPredict class. Error A corresponds to class
462	switching between HepatoPredict classes associated with a very high or high predicted benefit of LT,
463	respectively Class I and Class II [16]. Error B relates to a switch on HepatoPredict class with more impact
464	in the LT benefit, i.e., a switch from a class with no benefit to a class with LT benefit (Class 0 to Class I
465	or Class II) or from a class with LT benefit to a class with no benefit (Class I or Class II to Class 0). In
466	general, error A was ~1.6 times higher than error B (Figure 6E).



Figure 6 – Robustness of the HepatoPredict algorithm. Representation of errors associated with the univariate alteration of Cq mean values from each molecular variables before normalization (A), with the univariate alteration of the tumor number (B), or tumor size or total tumor volume (C). Errors associated with the univariate alteration of the molecular variables after normalization (D). Multivariate analyses of the HepatoPredict algorithm for distinct combinations of variables, ranging from 2 to 7 variables (E). The dashed line in light grey represents the errors at 5 %.

473 Discussion:

474 The HepatoPredict kit uses an algorithm that combines molecular data (gene expression levels of DPT, 475 CLU, CAPNS1, and SPRY2) with clinical variables (tumor number, size of the largest nodule, and total 476 tumor volume) to classify the patients in two different classes associated with the benefit of a liver 477 transplant (Class I – very high confidence, and Class II – high confidence) or in Class 0 (no benefit of liver 478 transplant predicted). Some products already exist in the market focused on the prognostic prediction 479 of different tumors, such as breast [24] and prostate [25], but nothing specific for HCC is available. 480 While the successful clinical validation of HepatoPredict kit using a retrospective cohort was previously 481 published [16], the herein described new version of HepatoPredict algorithm presents several 482 improvements. To start, the new HepatoPredict algorithm is associated with a higher PPV in Class I, 483 which allows for the selection of very likely good prognosis candidates for LT, a potential advantage in 484 geographies where the time in a LT waiting lists is very long. In addition, the new HepatoPredict 485 algorithm presents a higher negative predictive value (NPV) when compared with different clinical 486 criteria (such as Milan [4], UCSF [6], Up to seven [11], AFP [7], Metroticket 2.0 [5], TTV [13], and TTV 487 AFP [12] criteria). The higher NPV of HepatoPredict translates into a higher probability of being correct 488 in terms of detecting a bad prognosis patient when the kit result is Class 0 (no benefit of a LT). This 489 reduces the misclassifications of patients that benefit from a LT and can avoid wasting a healthy organ 490 in a patient that very likely will face HCC recurrence. This correct prognosis assignment was also 491 corroborated by the results of multivariate analysis of the HepatoPredict algorithm, demonstrating a 492 higher rate of type A errors (switch between Class I and II with benefit prediction) than type B errors 493 (from good prognosis to bad prognosis and vice-versa). To further corroborate the clinical utility of the 494 HepatoPredict kit additional retrospective studies are being planned enrolling patients' cohorts from 495 different geographic localizations and HCC etiologies and a prospective study (NCT0449983) is currently 496 open and recruiting.

497

498 In the context of analytical validation of multi-target genomic assays (such as HepatoPredict kit), no 499 evaluation guidelines covering all the relevant aspects required for the diagnostic setting are available. 500 To fill this gap, different guidelines such as ISO201395-2019 [19], MIQE [20], CLSI-MM16 [22], CLSI-501 MM17 [21], and CLSI-EP17-A [23] were followed where applicable, to demonstrate that the 502 HepatoPredict kit is a sensitive, specific, and robust test. Thus, the described analytical validation of the 503 HepatoPredict kit is in accordance with standard assay validation processes. This type of approach has 504 been previously used to validate similar prognostic [26-29] and diagnostic [30-32] tests and as a 505 reference for analytical validation of the test in different molecular pathology laboratories.

506

507 In diagnostic settings, FFPE is the most commonly used technique for long-term conservation of clinical 508 samples, since it preserves the proteins and vital structures within the tissue while it aids microscopic 509 diagnostic examination, experimental research, and diagnostic/drug development [33]. FFPE samples 510 were thus implemented for the HepatoPredict kit to simplify its adoption by molecular biology and 511 pathology laboratories. The RNA extraction method from FFPE HCC samples was demonstrated to be 512 repeatable (between duplicates) and reproducible (between operators). Regarding gDNA residual 513 contamination, Cq values above 34 in RT-qPCR reactions targeting Chr3 were observed in 1.15 and 514 9.19 % of the samples (for operator 1 and 2, respectively). However, the LoD for Chr3 was determined 515 at 33.95 Cq, meaning that above this Cq value, Chr3 detection is likely invalid, suggesting that gDNA 516 contamination during RNA extraction from HCC FFPE samples is very residual and approaching 0 % with 517 HepatoPredict kit.

518

The RNA extracted from FFPE tissues is normally fragmented [34], thus, FFPE sections were digested with heat application (56 °C) and proteinase K to decrease RNA fragmentation and chemical modifications [35,36]. Moreover, the primers of the HepatoPredict kit were designed for the generation of short amplicons to increase gene detection rate [17,37,38], and gene specific reverse transcription and targeted cDNA amplification (1-step RT-qPCR) were performed to increase the accuracy and

524 sensitivity of the RT-qPCR reactions [39]. Nevertheless, the HepatoPredict kit includes a sample quality 525 control step comprising 1-step RT-qPCR reactions targeting RPL13A and Chr3. With this procedure, it is 526 possible to determine if the extracted sample contains enough RNA (shown by the Cq value from 527 RPL13A) and if gDNA contamination is present (reported by the Cq value from Chr3) [17] before 528 proceeding with the kit protocol. This assessment is important because it assures the reproducibility 529 and veracity of the experiments, avoids extra costs associated with the need of repeating the analysis 530 and the wasting of precious tumor samples [20,40]. Considering that HepatoPredict analyses the 531 expression level of 7 different genes, Cq values for each target, allowing all targets to be detected within 532 their linear ranges and below their LoDs, were determined. Thus, an acceptable Cq range for the sample 533 quality control was defined for the *RPL13A* gene: 18.32 to 28.26 Cq. Regarding *Chr3*, all Cq values above 534 its LoD (33.95 Cq) are acceptable since they represent no gDNA contamination.

535

536 Regarding RT-qPCR reactions, primer specificity for each target included in the HepatoPredict kit was 537 demonstrated. Although probes (TaqMan[®] technology) are also included in the RT-qPCR reactions, they 538 were not analyzed in the context of sequencing because they do not amplify PCR products and because 539 their fluorescence is only released in the context of highly specific annealing to the target sequences in 540 the PCR amplicons. Thus, if the Sanger sequencing proves that each primer pair-related PCR amplicon 541 is specific and no unspecific PCR products are detected, each probe can only anneal to the amplified 542 specific product. To further demonstrate that the RT-qPCR reactions included in the HepatoPredict kit 543 could distinguish between target and non-target sequences, an inclusivity of 100 % was demonstrated 544 for all targets, excluding the DPT gene which had an inclusivity of 95 %. This result was expected since 545 the downregulation of the DPT gene in HCC has been demonstrated and can be already associated with 546 HCC carcinogenesis and progression [41–43]. In contrast with diagnostic systems [31], the exclusivity 547 of the RT-qPCR reactions was not studied since the HepatoPredict kit analyzes the expression level of 548 genes that are not exclusively expressed on HCC cells. Nevertheless, to be analyzed by HepatoPredict 549 kit, each HCC sample needs to be collected by expert clinicians (surgeons or radiologists) and subsequently analyzed at the microscopical level (H&E-stained tissue slides) by a certified pathologist, assuring the specificity of each HCC biopsy submitted to the HepatoPredict kit test. Furthermore, the sensitivity of the RT-qPCR reactions included in the HepatoPredict kit was determined by defining the LoD for each target, as well as the respective linear range. The amplification efficiency was also calculated for all targets being between 90 and 110 % as recommended by ISO 203095:2019.

555

556 The robustness of the qPCR reactions included in HepatoPredict kit was studied. It was demonstrated 557 that qPCR reactions were robust, not being affected by small changes either in annealing temperatures 558 and reagents' concentration and volumes.

559

560 Moreover, precision studies, assessing both the repeatability and reproducibility of the qPCR reactions 561 included in the HepatoPredict kit, demonstrated that the variability associated with normalized Cq 562 values for DPT, CLU, CAPNS1 and SPRY2 genes was not dependent on a single factor (day, lot, or 563 operator). Furthermore, the inter-assay SD within a sample is similar to the inter-assay SD between 18 564 samples, demonstrating the reproducibility of the assay independently of the sample used. The DPT 565 gene was associated with a higher SD in all assays, nevertheless no differences were observed in DPT 566 repeatability in comparison with the other targets. These results suggest that the lower reproducibility 567 of the DPT gene (i.e., higher SD), may be associated with DPT lower inclusivity (95%) due to DPT 568 downregulation in HCC [41-43].

569

The robustness of the new HepatoPredict algorithm was also studied and the acceptable variation range for each variable was determined. It was demonstrated that *DPT* gene expression level and total tumor volume were the most sensitive variables. This was expected since in the XGBoost model (first level), the *DPT* gene expression level and total tumor volume had an information gain of 3.75 and 0.29 (respectively), while the other variables had an information gain of zero. Moreover, the SVM model (second level), also corroborated these results since the variables with higher SVM weights were *DPT*

576	gene expression level, total tumor volume, and CLU gene expression level. Total tumor volume is
577	related to the number of tumors and tumor diameter measurements; thus, errors in these variables
578	will influence its value. A recent study described a mean error of 0.81 cm when measuring the tumor
579	size using different magnetic resonance imaging pulse sequences [44]. This was reflected in an
580	HepatoPredict type B error of 4.94%, demonstrating that the prognostic test handles common
581	measuring errors.
587	

- 582
- 583

584 Conclusions:

585	Despite the introduction of perturbations mimicking real-life observed variations to the molecular and
586	clinical variables, the prognostic information achieved with the HepatoPredict kit does not change.
587	Prognosis variation is only expected under extreme and combined variations of multiple variables,
588	unlikely to occur in real life. In addition, the technical validation procedures presented in this study can
589	be used as a reference for the analytical validation of the HepatoPredict test in different molecular
590	diagnostic laboratories. The performance of the presented analytical testing also demonstrates that the
591	HepatoPredict kit can be easily integrated into routine molecular diagnostic procedures to accurately
592	identify HCC patients more likely to benefit from a liver transplant, contributing to the implementation
593	of a true precision medicine.
594	
595	List of Abbreviations:
596	AFP: alpha-fetoprotein
597	DNA: Deoxyribonucleic acid
598	<i>Cl:</i> Confidence interval
599	<i>CLSI:</i> Clinical laboratory standards institute
600	<i>Cq:</i> Cycle threshold
601	<i>DCP:</i> des-γ carboxyprothrombin
602	FFPE: formalin-fixed paraffin-embedded
603	<i>gDNA:</i> Genomic DNA
604	HBV: Hepatitis B virus
605	HCC: Hepatocellular carcinoma
606	HCV: Hepatitis C virus
607	ISO: International organization for standardization
608	<i>LoB:</i> Limit of blank
609	<i>LoD:</i> Limit of detection

- 610 LT: Liver transplantation
- 611 *MIQE:* Minimum information for publication of quantitative real-time PCR experiments
- 612 *NPV:* Negative predictive value
- 613 NTC: No template control
- 614 *N/A:* Not applied
- 615 *p*: p-value
- 616 **RNA:** Ribonucleic acid
- 617 **RT-qPCR:** real-time quantitative reverse transcription polymerase chain reaction
- 618 SD: Standard deviation
- 619 STD: Standard
- 620 TTV: Total tumor volume
- 621 UCSF: University of California San Francisco
- 622
- 623 Declarations:
- 624 <u>Ethics approval and consent to participate</u>: The retrospective clinical study was approved by the ethics
- 625 authorities (Comissão de Ética para a Saúde) from the Centro Hospitalar de Lisboa Central (Process
- 626 number 144/2014). Being a retrospective study focused on tumoral tissue, the informed consent was
- 627 waived by the same ethics authorities referred above. Samples were used in accordance with the
- 628 Declaration of Helsinki.
- 629 <u>Consent for publication</u>: Not applicable.
- 630 Availability of data and materials: The datasets used and/or analyzed during the current study are
- 631 available from the corresponding author on reasonable request.
- 632 <u>Competing interests</u>: The work described here is subject to patent WO 2021/064230 A1; JPL, JC, and
- 633 HPM declare an ownership interest in the company Ophiomics. MGR, DP, LPF, and JLN are employees
- 634 at Ophiomics. SS has no competing interests.

<u>Funding</u>: This work was partly funded by a grant from the European Innovation Council under the EIC
Accelerator scheme (Contract Nº946364).

- <u>Authors' contributions</u>: MGR and JC conceived and designed the study. MGR and DP performed the
 experiments. MGR, LPF, JLN, and JC analyzed and interpreted the data. LPF drafted the manuscript. SS
 and HPM coordinated clinical sample collection. MGR, DP, JLN, JBPL, JC edited and revised the
 manuscript. All authors read and approved the final manuscript.
- 641 <u>Acknowledgements</u>: The authors wish to thank to the patients, to *Neuralshift* and to the pathology
- team from the Curry Cabral Hospital, particularly Clara Rodrigues and António Figueiredo. Moreover,
- the authors particularly acknowledge the Biobank IRBLleida (PT20/00021) integrated in the Spanish
- 644 National Biobanks Network and Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director
- 645 d'Oncología Catalunya (XBTC), as well as the Biobank ISABIAL integrated in the Spanish National
- 646 Biobanks Network and in the Valencia Biobanking Network for their collaboration.
- 647

648 **References:**

- 649 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics
- 650 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA
- 651 Cancer J Clin. Wiley; 2021;71:209–49.
- 652 2. Silva MF, Sherman M. Criteria for liver transplantation for HCC: What should the limits be? J Hepatol.
- 653 Elsevier B.V.; 2011;55:1137–47.
- 654 3. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of
- 655 patients with hepatocellular carcinoma according to underlying disease and treatment modalities.
- 656 Medicine (United States). Lippincott Williams and Wilkins; 2017;96:e5904.
- 4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for
 the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. M;
 1996;334:693–702.

- 5. Mazzaferro V, Sposito C, Zhou J, Pinna AD, de Carlis L, Fan J, et al. Metroticket 2.0 Model for Analysis
- 661 of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
 662 Gastroenterology. W.B. Saunders; 2018;154:128–39.
- 663 6. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for
- 664 hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival.
- 665 Hepatology. W.B. Saunders; 2001;33:1394–403.
- 666 7. Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, et al. Validation of the AFP
- 667 model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had 668 received a liver transplant for HCC. J Hepatol. Elsevier B.V.; 2017;66:552–9.
- 669 8. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera J v., et al. Recurrence
- after liver transplantation for hepatocellular carcinoma. Ann Surg. Lippincott Williams and Wilkins;
 2017;265:557–64.
- 9. Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, et al. The Tumor Burden Score:
- A New "metro-ticket" Prognostic Tool for Colorectal Liver Metastases Based on Tumor Size and Number
- 674 of Tumors. Ann Surg. Lippincott Williams and Wilkins; 2018;267:132–41.
- 10. Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, et al. Usefulness of the Kyoto criteria as
- 676 expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery (United677 States). 2013;154:1053–60.
- 678 11. Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: A
- 679 single center analysis. World J Gastroenterol. Baishideng Publishing Group Co; 2013;19:6077–83.
- 680 12. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, et al. Total Tumor
- 681 Volume and Alpha-Fetoprotein for Selection of Transplant Candidates With Hepatocellular Carcinoma:
- A Prospective Validation. Hepatology. John Wiley and Sons Inc; 2015;62:158–65.
- 683 13. Macaron C, Hanouneh IA, Lopez R, Aucejo F, Zein NN. Total tumor volume predicts recurrence of
- 684 hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
- 685 Transplant Proc. 2010. p. 4585–92.

686 14. Mehta N. Liver Transplantation Criteria for Hepatocellular Carcinoma, including Posttransplant
687 Management. Clin Liver Dis (Hoboken). 2021;17:332–6.

- 688 15. Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular689 carcinoma: Where do we stand? World J Gastroenterol. Baishideng Publishing Group Co;
- **690** 2019;25:2591–602.
- 691 16. Pinto-Marques H, Cardoso J, Silva S, Neto JL, Gonçalves-Reis M, Proença D, et al. A gene expression
- 692 signature to select hepatocellular carcinoma patients for liver transplantation. Ann Surg. 2022;

693 17. Antonov J, Goldstein DR, Oberli A, Baltzer A, Pirotta M, Fleischmann A, et al. Reliable gene 694 expression measurements from degraded RNA by quantitative real-time PCR depend on short

amplicons and a proper normalization. Laboratory Investigation. 2005;85:1040–50.

- 696 18. Plackett RL, Burman JP. Biometrika Trust The Design of Optimum Multifactorial Experiments.697 Biometrika. 1946;33:305–25.
- 698 19. International Organisation of Standardization. ISO 20395:2019. Biotechnology Requirements for
- 699 evaluating the performance of quantification methods for nucleic acid target sequences qPCR and

700 dPCR. ISO 20395:2019. International Organisation of Standardization; 2019.

- 20. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines:
- 702 Minimum information for publication of quantitative real-time PCR experiments. Clin Chem.703 2009;55:611–22.
- 704 21. Clinical & Laboratory Standards Institute (CLSI). Verification and validation of multiplex nucleic acid
- assays. CLSI document MM17-A. Clinical and Laboratory Standards Institute; 2008.
- 706 22. Clinical & Laboratory Standards Institute (CLSI). Use of external RNA controls in gene expression
- assays. CLSI document MM16-A. Clinical and Laboratory Standards Institute; 2006.
- 708 23. Clinical & Laboratory Standards Institute (CLSI). Protocols for determination of limits of detection
- and limits of quantitation. NCCLS document EP17-A. NCCLS; 2004.

- 710 24. Varnier R, Sajous C, de Talhouet S, Smentek C, Péron J, You B, et al. Using breast cancer gene
- 711 expression signatures in clinical practice: unsolved issues, ongoing trials and future perspectives.
- 712 Cancers (Basel). MDPI; 2021;13:1–24.
- 713 25. Choudhury A, West CML. Translating prognostic prostate cancer gene signatures into the clinic.
- 714 Transl Cancer Res. AME Publishing Company; 2017. p. S405–8.
- 715 26. Kronenwett R, Bohmann K, Prinzler J, Sinn B v., Haufe F, Roth C, et al. Decentral gene expression
- analysis: Analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
- 717 BMC Cancer. 2012;12.
- 718 27. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the oncotype
- 719 DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-
- negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53:1084–91.
- 28. Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, et al. Technical validation of an RT-qPCR
 in vitro diagnostic test system for the determination of breast cancer molecular subtypes by
- quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded
- breast tumor specimens. BMC Cancer. BioMed Central Ltd.; 2016;16.
- 725 29. Gruselle O, Coche T, Louahed J. Development of a quantitative real-time RT-PCR assay for the
- detection of MAGE-A3-positive tumors. Journal of Molecular Diagnostics. Elsevier B.V.; 2015;17:382–
- 727 91.
- 30. Potter NT, Hurban P, White MN, Whitlock KD, Lofton-Day CE, Tetzner R, et al. Validation of a real-
- time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin
- 730 Chem. American Association for Clinical Chemistry Inc.; 2014;60:1183–91.
- 731 31. Brown JT, Beldorth IJ, Laosinchai-Wolf W, Fahey ME, Jefferson KL, Ruskin AK, et al. Analytical
- 732 Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting
- 733 BCR-ABL1 RNA. Journal of Molecular Diagnostics. Elsevier B.V.; 2019;21:718–33.

- 32. Gürtler C, Laible M, Schwabe W, Steinhäuser H, Li X, Liu S, et al. Transferring a Quantitative
 Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR Platforms. Journal of Molecular
- 736 Diagnostics. Elsevier B.V.; 2018;20:398–414.
- 737 33. Seiler C, Sharpe A, Barrett JC, Harrington EA, Jones E v., Marshall GB. Nucleic acid extraction from
- formalin-fixed paraffin-embedded cancer cell line samples: a trade off between quantity and quality?
- 739 BMC Clin Pathol. BioMed Central; 2016;16:1–13.
- 34. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPEsamples. PLoS One. 2007;2.
- 742 35. Chung J-Y, Braunschweig T, Hewitt SM. Optimization of Recovery of RNA From Formalin-fixed,
- Paraffin-embedded Tissue. Diagnostic Molecular [Internet]. 2006; Available from:
 www.cancer.gov/tarp
- 745 36. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA
- from formalin-fixed samples and optimization of molecular biology applications for such samples.
 Nucleic Acids Res. 1999;27:4436–43.
- 37. Specht K, Richter T, Mü U, Walch A, Werner M, Hö H. Technical Advance Quantitative Gene
 Expression Analysis in Microdissected Archival Formalin-Fixed and Paraffin-Embedded Tumor Tissue.
- American Journal of Pathology. 2001;158.
- 751 38. Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, Pinto-Marín Á, Hardisson D, López R, et al.
- 752 Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen
- and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques. Eaton Publishing
 Company; 2010;48:389–97.
- 755 39. Zeka F, Vanderheyden K, de Smet E, Cuvelier CA, Mestdagh P, Vandesompele J. Straightforward and
- sensitive RT-qPCR based gene expression analysis of FFPE samples. Sci Rep. Nature Publishing Group;
 2016;6.
- 40. Die J v., Román B. RNA quality assessment: a view from plant qPCR studies. J Exp Bot. Oxford
 University Press; 2012;63:6069–77.

- 41. Fu Y, Feng M-X, Yu J, Ma M-Z, Liu X-J, Li J, et al. DNA methylation-mediated silencing of matricellular
- 761 protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase
- 762 signaling. Oncotarget [Internet]. 2014;5:6701–15. Available from:
- 763 www.impactjournals.com/oncotarget/
- 42. Li X, Feng P, Ou J, Luo Z, Dai P, Wei D, et al. Dermatopontin is expressed in human liver and is
- 765 downregulated in hepatocellular carcinoma. Biochemistry (Moscow). Maik Nauka-Interperiodica
- 766 Publishing; 2009;74:979–85.
- 43. Liu S, Qiu J, He G, Geng C, He W, Liu C, et al. Dermatopontin inhibits WNT signaling pathway via
- 768 CXXC finger protein 4 in hepatocellular carcinoma. J Cancer. Ivyspring International Publisher;
- 769 2020;11:6288–98.
- 44. Armbruster M, Guba M, Andrassy J, Rentsch M, Schwarze V, Rübenthaler J, et al. Measuring hcc
- tumor size in mri—the sequence matters! Diagnostics. MDPI; 2021;11.
- 772
- 773
- 774